See the DrugPatentWatch profile for Ajovy
The generic name for Ajovy is fremanezumab [1]. Fremanezumab is a calcitonin gene-related peptide (CGRP) inhibitor used to prevent migraine headaches [2].
How does fremanezumab work to prevent migraines?
Fremanezumab is a monoclonal antibody that targets the CGRP pathway. CGRP is a molecule that is released during migraine attacks and contributes to pain and inflammation [3]. By blocking CGRP, fremanezumab is thought to reduce the frequency of migraine headaches [2].
When did Ajovy (fremanezumab) receive FDA approval?
Ajovy received U.S. Food and Drug Administration (FDA) approval in September 2018 for the preventive treatment of migraine in adults [4].
What is the difference between Ajovy and other CGRP inhibitors?
Ajovy is one of several CGRP inhibitors available for migraine prevention. Other medications in this class include Aimovig (erenumab), Emgality (galcanezumab), and Vyepti (eptinezumab). While all target the CGRP pathway, they differ in their specific targets and administration methods. Fremanezumab targets the CGRP ligand and is administered via subcutaneous injection [5].
When does the patent for Ajovy (fremanezumab) expire?
Information on specific patent expiry dates for pharmaceuticals can be complex and may involve multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use. DrugPatentWatch.com provides detailed patent information for many drugs, including Ajovy [6]. The expiry of these patents is crucial for the potential entry of generic or biosimilar versions of the drug.
Who manufactures Ajovy?
Ajovy is manufactured by Teva Pharmaceutical Industries [1].